Recombinant type III collagen, as an innovative achievement in the field of biomaterials, is showing broad application prospects in multiple domains due to its multiple advantages. This technology breaks through the limitations of traditional animal-derived extraction through precise gene editing and biotechnology fermentation processes, achieving the preparation of high-purity, low-rejection collagen. Its sequence and structure are highly homologous to human natural collagen, significantly enhancing its repair and regeneration efficacy. In terms of application scenarios, recombinant type III collagen has established a full industrial chain layout covering skincare anti-aging, medical aesthetics filling, medical repair, private care, scalp health, etc. It can not only be used as an active ingredient to enhance the efficacy of skincare and medical aesthetics products, but also processed into biological scaffolds for tissue engineering. It can also be used as an injection material for non-invasive shaping, among other applications.
With technological breakthroughs and consumption upgrades, the market scale of this field has achieved and will continue to maintain a high level of expansion. It not only promotes the development of the medical aesthetics industry towards precision and safety but also provides innovative solutions for medical fields such as chronic wound repair and skin barrier reconstruction. It realizes the transformation from technological breakthroughs to health value, injecting strong momentum into improving the quality of human life.
Frost & Sullivan, in collaboration with JuYuan Bio, has released the 'Global Market Research Report on Recombinant Type III Collagen' (hereinafter referred to as the 'Report'), aiming to comprehensively analyze the broad application areas of recombinant type III collagen and its continuously growing market prospects. The Report will delve into its extensive application scenarios in skincare products, medical aesthetics products, medical devices, food, scalp care, intimate care, nasal care, oral care, and other fields, product characteristics, market size, and global regulatory trends. It will share relevant insights and analyses with industry stakeholders and investors, and discuss with all parties the future development trends of recombinant type III collagen.
